Clinical trial · Interventional
Green Tea Extract and Prostate Cancer
NCT00676780CI-TRIAL-00007790completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to see if a green tea extract can beneficially alter several markers of cancer risk and progression.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Polyphenon E (EGCG) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- ECGC Extract
- description
- Single arm for a phase II study
- interventionNames
- Drug: Polyphenon E (EGCG)
Primary outcomes (3)
- measure
- Change in Serum Prostate Specific Antigen (PSA) of Prostate Cancer
- timeFrame
- Baseline and 6 weeks
- description
- Change in serum prostate specific antigen (PSA) from baseline to post Polyphenol E treatment.
- measure
- Change in Serum Vascular Endothelial Growth Factor (VEGF) and Prostate Cancer.
- timeFrame
- Baseline and 6 weeks.
- description
- Change in serum vascular endothelial growth factor (VEGF) from baseline to post Polyphenol E treatment.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * recent biopsy positive for prostate cancer * scheduled for prostatectomy * must be able to swallow capsules * Palpable mass by digital rectal examination (DRE) * Ability to give informed consent and willingness to adhere to study protocol * Age ≥ 18 years and less than 75 Exclusion Criteria: * abnormal liver function * Prior hormonal or surgical therapy for prostate cancer * Liver or kidney problems that would interfere with metabolism of study drug * Any condition that would hamper informed consent or ability to comply with study protocol * Participation in another research study in the last three months * Known malignancy at any site other than prostate * Recent consumption of green tea (5 or more cups per day, within one week prior to biopsy)
References
Publications (1)
- RESULTMcLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila). 2009 Jul;2(7):673-82. doi: 10.1158/1940-6207.CAPR-08-0167. Epub 2009 Jun 19. PMID 19542190